For Media Inquiries, Please Contact:
Jordan Berman
Vice President,
Global Corporate Communications
Apotex Inc.
150
Signet Drive
North York,
ON, M9L 1T9
Canada
416-401-7487
Email
Press Center
-
June 1, 2018Health Canada Leads the Way by Approving the First-Ever Pegfilgrastim Biosimilar in any Highly Regulated World Market
-
September 1, 2017
-
February 9, 2017
-
March 31, 2016Apobiologix®, a Division of Apotex Inc., today launched Grastofil®, its first subsequent entry biologic (SEB) approved in Canada.
-
March 24, 2016Apotex Inc. announced today that it has launched the first generic version of Merck's Nasonex® nasal spray (mometasone furoate monohydrate) in the United States.